56
RESEARCH AND CLINICAL TRIALS
>$ 6 Million
Cardiovascular research grants – Dallas and Fort Worth sites ( FY20 )
Fiscal year 2020 was a year punctuated with a robust roster of clinical trials and studies conducted by cardiovascular investigators in Dallas through Baylor Scott & White Heart and Vascular Institute and Soltero Cardiovascular Research Center , a part of Baylor Scott & White Research Institute . In addition , the studies conducted at Baylor Scott & White Heart and Vascular Hospital – Fort Worth through Baylor Scott & White Research Institute continued to expand , offering increased opportunities for residents of Tarrant and surrounding counties to participate in groundbreaking studies aimed at benefitting future heart and vascular patients .
For a complete listing of clinical trials and the principal investigators : BRITrials
. BSWSites . com
In addition to the work on cardiovascular clinical trials and studies , cardiologists on the medical staff were also involved in targeted studies related to the onset of COVID-19 . Using their experience with specific medications , this group of heart specialists participated in national trials to help identify mechanisms engineered to slow the coronavirus pandemic and / or lessen the severity of the illness in patients . This work took on added importance as researchers and physicians began to recognize the collateral damage the virus was causing to the heart and vascular systems .
Cardiologists involved in COVID-19 related studies
Heart failure specialist on the medical staff , Robert L . Gottlieb , MD , PhD , FACC , is the co-principal investigator for the Baylor Scott & White Research Institute ’ s Dallas site to study the antiviral drug remdesivir , collaborating with Gilead Sciences , to treat people who are severely ill with COVID-19 . The Dallas site was one of 180 hospitals participating in the worldwide study fasttracked during the height of the COVID-19 pandemic . Study results in June 2019 indicated that the drug helps shorten the illness time and the severity of the virus , decreasing morbidity by 62 %. Furthermore , the study indicates that the drug provided over fewer days was as effective as providing dosing for 10 days . At the time of printing , the results continue to be reviewed , but indications are promising .
Chief medical officer for Baylor Scott & White Heart and Vascular Hospital , Kevin Wheelan , MD , FACC , and the medical director for cardiovascular research and education for Baylor Scott & White Heart and Vascular Institute ( Dallas ), Peter McCullough , MD , MPH , FACC , FACP , FAHA , FCCP , FNKF , FNLA , FCRSA , were principal investigators in work on the Dallas campus related to the prophylactic use of hydroxychloroquine in healthcare workers and antibody responses to COVID-19 in asymptomatic healthcare workers . They have championed outpatient treatment strategies at a national level advocating for patient care guidelines with the U . S . Food and Drug Administration and National Institutes of Health . Dr . McCullough has more than six publications on COVID-19 related work to date of this printing .
NATIONALLY RECOGNIZED TOP ENROLLING STUDIES
BIOFLOW – Ranked # 1 enrolling site nationwide . Baylor Scott & White Research Institute
EVOLVE 48 – Ranked # 1 enrolling site nationwide . Baylor Scott & White Research Institute
ONYX SHORT DAPT – Ranked # 1 enrolling site nationwide . Baylor Scott & White Research Institute
SPYRAL ON MED – Ranked # 1 enrolling site nationwide . Ranked # 1 enrolling site for randomizations . Soltero Cardiovascular Research Center , a part of Baylor Scott & White Research Institute
SPYRAL OFF Med – Ranked # 1 for enrollments nationwide . Ranked # 2 in Pivotal Top US site . Ranked # 3 enrolling site for Randomizations . Soltero Cardiovascular Research Center